Risk Management & Treatment

Biomarkers used for treatment selection

The following tumor biomarkers may be used to select treatment for the cancer types listed below. Speak with your doctor about other biomarker tests and treatments, which may be available. 

Biomarker Cancer Treatment/s
  Breast Colorectal Endometrial Melanoma Ovarian Pancreatic Prostate

 

BRAFV600E   X   X      

Braftovi (encorafenib)
Braftovi in combination with Mektovi (binimetinib)
Cotellic (cobimetinib)
Zelboraf (vemurafenib) 

BRCA1, BRCA2          X   X Lynparza (olaparib) 
Rubraca (rucaparib)
Zejula® (niraparib)
Epidermal growth factor
receptor (EGFR) mutation testing
  X          

Erbitux (cetuximab)
Vectibix (panitumumab) 

Estrogen/Progesterone receptor
(ER/PR) expression
X   X        

Aromatase inhibitors (AIs)
Tamoxifen
Raloxifene

Her2neu overexpression X             Herceptin (trastuzumab)
Perjeta (pertuzumab)
Tuksya (tucatinib)
Kadcyla (ado-trastuzumab emtansine) 
Homologous Recombination
Deficiency (HRD)
        X    

Lynparza (olaparib) 
Zejula® (niraparib)

Homologous Recombination Response (HRR) pathway mutations (ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK2, FANCL, PALB2, RAD51B, RAD51CRAD51D, RAD54)             X Lynparza (olaparib) 
KRAS mutation   X          

Erbitux (cetuximab)
Vectibix (panitumumab) 

MSI-H (Microsatellite Instability) or MMR-D (Mismatch Repair) X X X X X X X Keytruda (pembrolizumab)
MSI-H (Microsatellite Instability) or MMR-D (Mismatch Repair)   X           Opdivo (nivolumab) 
Yervoy (ipilimumab)
NTRK fusion X X X X X X X Vitrakvi (larotrectinib)
PDL1 expression X             Tecentriq (atezolizumab)
PIK3CA X             Piqray (alpelisib),
Tumor Mutational Burden (TMB) X X X X X X X Keytruda (pembrolizumab)
Last updated July 05, 2020